MENU
+Compare
PPH
ETF ticker: NASDAQ
AS OF
Feb 21, 04:59 PM (EDT)
Price
$91.24
Change
+$0.90 (+1.00%)
Net Assets
586.04M

PPH stock forecast, quote, news & analysis

Category: @Health
PPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for PPH with price predictions
Feb 20, 2025

Aroon Indicator for PPH shows an upward move is likely

PPH's Aroon Indicator triggered a bullish signal on February 18, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 292 similar instances where the Aroon Indicator showed a similar pattern. In of the 292 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 18, 2025. You may want to consider a long position or call options on PPH as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PPH just turned positive on February 20, 2025. Looking at past instances where PPH's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

PPH moved above its 50-day moving average on January 24, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PPH crossed bullishly above the 50-day moving average on January 31, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PPH advanced for three days, in of 335 cases, the price rose further within the following month. The odds of a continued upward trend are .

PPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for PPH moved out of overbought territory on January 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where PPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), McKesson Corp (NYSE:MCK), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Pharmaceutical ETF ETF is 140.32B. The market cap for tickers in the group ranges from 2.48B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is PDCO at 2.48B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Pharmaceutical ETF ETF was 19%. For the same ETF, the average monthly price growth was 19%, and the average quarterly price growth was 26%. BHC experienced the highest price growth at 13%, while ZTS experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the VanEck Pharmaceutical ETF ETF was -15%. For the same stocks of the ETF, the average monthly volume growth was -21% and the average quarterly volume growth was 54%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 35
P/E Growth Rating: 57
Price Growth Rating: 53
SMR Rating: 57
Profit Risk Rating: 61
Seasonality Score: -55 (-100 ... +100)
View a ticker or compare two or three
PPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
335 Madison Ave.19th FloorNew York
Phone
888-658-8287
Web
www.marketvectorsetfs.com